HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
Stocks · News reference
RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462
RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $826
BTIG analyst Kambiz Yazdi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $810 to $826.
Praxis Precision Medicine Q2 2026 Earnings Call Transcript
Praxis Precision Medicine (NASDAQ:PRAX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call
Needham Reiterates Buy on Praxis Precision Medicine, Maintains $582 Price Target
Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $582 price target.